A. Li

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).

H. Wildiers, J. Jassem, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer profile and risk stratification of patients treated at Universitas Annex Department of Oncology, Bloemfontein, Free State, during 2008 to 2010

G. Joubert, A. Li, A. Sherriff, 2015 .

P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients

S. Banerji, Q. Chu, R. Juergens, 2017 .

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer.

O. Sartor, W. Figg, A. Li, 1998, Urology.

P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression

Jin-Ji Yang, W. Zhong, Z. Xie, 2017 .

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

J. Warner, T. Choueiri, M. Galsky, 2021, Annals of Oncology.

193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment.

E. Felip, J. V. van Meerbeeck, J. Wolf, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.